Interaction Mechanism Between the HSV-1 Glycoprotein B and the Antimicrobial Peptide Amyloid-β

Abstract

Background:

Unravelling the mystery of Alzheimer’s disease (AD) requires urgent resolution given the worldwide increase of the aging population. There is a growing concern that the current leading AD hypothesis, the amyloid cascade hypothesis, does not stand up to validation with respect to emerging new data. Indeed, several paradoxes are being discussed in the literature, for instance, both the deposition of the amyloid-β peptide (Aβ) and the intracellular neurofibrillary tangles could occur within the brain without any cognitive pathology. Thus, these paradoxes suggest that something more fundamental is at play in the onset of the disease and other key and related pathomechanisms must be investigated.

Objective:

The present study follows our previous investigations on the infectious hypothesis, which posits that some pathogens are linked to late onset AD. Our studies also build upon the finding that Aβ is a powerful antimicrobial agent, produced by neurons in response to viral infection, capable of inhibiting pathogens as observed in in vitro experiments. Herein, we ask what are the molecular mechanisms in play when Aβ neutralizes infectious pathogens?

Methods:

To answer this question, we probed at nanoscale lengths with FRET (Förster Resonance Energy Transfer), the interaction between Aβ peptides and glycoprotein B (responsible of virus-cell binding) within the HSV-1 virion

Results:

The experiments show an energy transfer between Aβ peptides and glycoprotein B when membrane is intact. No energy transfer occurs after membrane disruption or treatment with blocking antibody.

Conclusion:

We concluded that Aβ insert into viral membrane, close to glycoprotein B, and participate in virus neutralization.

Keywords

Alzheimer’s disease amyloid-beta FRET HSV-1 glycoprotein B interaction

INTRODUCTION

Alzheimer’s disease (AD) is the leading cause of dementia in the world, mainly due to the global increase of the aging population, as age is one of the most important risk factors for developing AD. Despite intense research efforts, we still do not know the exact causes of late onset AD. Nevertheless, there is a general agreement that AD’s prime histopathological signature led to the so-called Amyloid Cascade Hypothesis (ACH), involving plaques induced by amyloid-β (Aβ) peptides and of intracellular neurofibrillary tangle deposition [1]. However, several paradoxes forced us to expand this view of ACH and reconcile it with novel emerging data; for example: 1) Aβ peptide deposition can occur in cognitively normal individuals [2 –4]; 2) Aβ peptides are abundant in the mild cognitive impairment stage of AD and decrease in some clinically diagnosed AD [5]; 3) inflammation precedes Aβ peptide deposition [6]; and 4) current data support the view that aberrant processing of the amyloid-β protein precursor (AβPP) towards Aβ peptides, may sometimes cause human familial/early onset AD. All current data do not support the conclusion that aberrant Aβ peptide expression is the cause of late onset AD but likely only plays a secondary role as part of a more complex process. A compelling (yet controversial) body of data is mounting, which can be reconciled with ACH and potentially explain the above paradoxes. This data has its origin in a hypothesis by Dr. O. Fischer in 1910, which posited that infectious pathogens are involved in AD since senile plaques are reminiscent of bacterial colonies [7]. Independent research (including ours) has been instrumental in corroborating the infectious hypothesis by showing that, in fact, a family of microorganisms (e.g., HSV-1, spirochetes, P. gingivalis) are potentially associated with late onset AD, also hinting that sporadic AD is a syndrome [5, 8]. As a case in point, DNA of HSV-1 has been found in AD patients’ senile plaques [9]. Moreover, several groups have demonstrated that the Aβ peptide is a powerful antimicrobial peptide, secreted by neurons, in response to attacks by microorganisms. This demonstration called Amyloid Protection Hypothesis (APH) lends weight to the infection hypothesis (IH) [10 –12]. Thus, under APH/IH theory, Aβ peptide accumulation is no longer seen as Aβ being the main participant in the pathophysiology of AD, but rather as an innate immune response element (i.e., reversing its role). Thus, senile plaques are possibly a byproduct of Aβ fighting to contain and neutralize infections [13].

As HSV-1 is a recognized culprit to foment APH/IH, its interaction with Aβ is of considerable interest. HSV-1 is an enveloped virus responsible mostly for cold sores, which stay latent in neurons throughout life and reactivate regularly inside the brain, in case of fatigue or decrease in immunity. Initially, it was demonstrated that AβPP, the precursor of Aβ, associates intracellularly with HSV-1 and contributes to the movement of the virus towards the cell surface (anterograde transport) with the help of glycoprotein D (gD) at the virus surface [14, 15]. It has been shown that pathogens and particularly HSV-1, interfere with the AβPP metabolic pathway and use C99 protein (specifically, the final 15 amino-acid sequence), rather than Aβ, to co-opt the intracellular transport machinery, enabling their transport along microtubules, but also causing neurofibrillary tangles [14 –16]. Moreover, studies demonstrate that AβPP C-terminal fragment, C99 protein, but not Aβ peptide is associated with neuronal death [17].

The interaction between viruses and amyloid peptides is under intense investigations to confirm the pathogenic role of viruses in various diseases, including neurodegenerative diseases. In most cases, the interaction is studied as the putative cause of the viral pathogenesis by inducing amyloid aggregation. Recently, the interaction between viral proteins including HSV-1 and the Aβ₄₂ peptide, has been reassessed in different settings by taking advantage of the resemblance of HSV-1 with nanoparticles, which have been shown to act as catalytic surfaces, that facilitate heterogenous nucleation of amyloid fibrils via binding, concentrating, and enabling conformational changes of amyloidogenic peptides [18 –20]. It has been demonstrated that HSV-1 accelerated the kinetics of Aβ₄₂ peptide aggregation and to a lesser extent that of Aβ₄₀ peptides [21, 22]. The authors have demonstrated an interaction between amyloid fibrils and the viral surface at different stages of maturation via early protofibrillar intermediates. They also observed that HSV-1 infection led to increased accumulation of amyloid plaques in a mouse model of AD. In their discussion, the authors try to reconcile the antimicrobial characteristics and the virus induced nucleation process, leading to amyloid plaques. Certainly, this is not mutually exclusive as we have shown that, at the beginning, the Aβ₄₂ peptide secreted by cells is antimicrobial but as the infection is progressing, it becomes pathogenic, by the virtue of the process described by Ezzat et al. This reminds us of the capacity of bacteria to form biofilm which mimic plaques and the fact that biofilms have already been demonstrated in AD [23]. These studies focused only on the putative pathogenic interaction of HSV-1 and Aβ₄₂ peptides, resulting in amyloid plaque formation, rather than the antimicrobial interaction of Aβ₄₂ against HSV-1. Indeed, these studies have presented corona formation as an essential step in the viral infection.

Enveloped viruses like HSV-1 have a core of viral nucleic acid surrounded by capsomers to form a capsid, then surrounded by a membrane derived from the host. Viral proteins, usually glycoproteins have been inserted into this membrane prior to encapsidation. They serve to allow attachment of progeny virions to a new host and then interactions between these glycoproteins promotes fusion of the viral and cellular membranes and allows the viral capsid to enter the cell. We have demonstrated earlier that the Aβ peptide, as antimicrobial peptide, prevents HSV-1 infection [10, 24]. Indeed, we have demonstrated that the addition of Aβ peptides to the culture media before or at the same time as HSV-1, decreases virus infectivity, while adding Aβ peptides when HSV-1 has already entered the neurons, shows no effect [24]. Moreover, HSV-1-infected neuronal supernatants, when added to new neuronal cultures, were also able to inhibit infection by HSV-1, presumably due to induced production of Aβ by cells after infection and released in supernatants [10]. This accumulating evidence has led us to ask about the molecular mechanisms of the action of Aβ peptides against AD pathogens.

Taking these data into consideration, it appears highly important to explore the currently unknown mechanism whereby Aβ peptides render HSV-1 non-infectious. At the surface of viruses, besides gD and among others, there also is the glycoprotein B (gB), a transmembrane protein involved in cell attachment and fusion. In a review in 2016 [13], we have shown that Aβ and gB shared sequence similarities and given the fact that Aβ could insert into microbial membranes and form pores to disrupt them [25, 26], we hypothesized that Aβ could also insert into the HSV-1 membrane near gB, and the pores produced would prevent viral infectivity either by disrupting the mechanism of fusion of the viral membrane with the cellular membrane or by allowing enzymes to enter the viral capsid and digest viral proteins or DNA. This potential gB-Aβ peptide interaction could also be extended to other enveloped viruses, as well as peptides, and could represent a threshold when it becomes inefficient and pathological.

Thus, the aim of the present study was to gather more experimental data to determine the antiviral mechanism of Aβ peptides against HSV-1 virus.

MATERIALS AND METHODS

Sequence alignment and antimicrobial prediction

The amino acid sequence alignment between HSV-1 gB and Aβ₄₂ was performed using the PyMol software after having depicted the 3D structure of HSV-1-gB and Aβ₄₂ peptide (The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC [27]).

AntiBP2 software was used, with neural networks and support vector machines (SVM) to predict the amino-acid sub-sequence for a peptide with antibacterial activity. AntiBP2 utilizes four datasets to train their models: N-terminus based, C-terminus based, N+C terminus based and amino acid composition methods. These 4 methods are SVM trained on 4 different datasets, compiled using N, C, NC, and full composition peptides respectively. For antiviral activity predictions, we employed the AVPpred software, which computes various features (i.e., motifs and alignments, followed by amino acid composition and physicochemical properties), during 5-fold cross validation using SVM. In particular, we have fragmented the amino sequence into subsequences of lengths 15, while taking the overlap length to be 14 and finally the subsequences of length 15 were processed by AVPred [28].

Förster resonance energy transfer (FRET)

The Förster resonance energy transfer (FRET) has been performed in a LightCycler480 II (Roche, Canada) with variable excitation and detection filters. 1μg of a recombinant HSV-1 containing the green fluorescent protein (GFP) integrated into gB (HSV-1-gB-GFP) produced at the Cochin Institute, Paris, France and kindly provided by Pr. Flore Rozenberg [29] was mixed with 1μg of Aβ₄₂-HiLyteFluor-555 (Anaspec, Fremont, CA), with or without various pre-treatments (see below) and controls, without cells, directly in wells of a 96-well plate at room temperature. Plates were sealed, centrifuged, and then processed by the thermocycler. Thermocycler conditions were heating 5 min to reach 37°C, then fluorescence acquisition every 10 min for 30 min, before cooling. Fluorescence acquisition was measured with excitation at 440 nm and emission at 580 nm (green fluorescence) and also with excitation at 440 nm and emission at 660 nm (red fluorescence). Several controls were also tested with the same program. Pre-treatments included mixing Aβ₄₂-HiLyteFluor-555 with 1μg of blocking antibodies (α-Aβ₄₂-Ab, Anaspec, Fremont, CA) for 15 min at room temperature prior to adding viral particles or pretreating the HSV-1-gB-GFP for 30 min at room temperature with 1% NP40 diluted in PBS, pH 7, to disrupt the viral envelope, before mixing with Aβ₄₂-HiLyteFluor-555. Controls included negative controls without virus or Aβ₄₂-HiLyteFluor-555, virus alone, and Aβ₄₂-HiLyteFluor-555 alone.

At the end of the program, the thermocycler software gave fluorescence values for green and red fluorescence for each well. Data obtained for each measure were averaged and used to create the graph.

Statistical analysis was performed using two-tailed unpaired T-test.

RESULTS

We first depict the 3D structure of HSV-1-gB and Aβ₄₂ peptides (Fig. 1A). Sequence homology was observed between the viral gB protein and Aβ ₄₂ (Fig. 1B and [13]). Furthermore, the antibacterial predictions show that a subsequence containing the helix and C-terminus of Aβ₄₂ peptide has antiviral activity (Fig. 1C and [22]). This result prompted us to analyze the interaction between HSV-1 and Aβ peptides on in vitro experiments.

Fig. 1

Molecular structure, sequence alignment, and anti-pathogenic property of Aβ. A) 3D crystal structure of HSV-1-gB and Aβ₄₂; data from PDB (RCSB Protein Data Bank, http://www.rcsb.org) are shown using PyMol software. Center panel shows zoom on HSV-1 gB intermembrane sequence with formed coils. B) Sequence alignment between HSV-1-gB and Aβ₄₂ (using PyMol software). C) Prediction of amino-acid sub sequences of Aβ₄₂ possessing antibacterial activity via AntiBP2 software (http://crdd.osdd.net/raghava/antibp2) and antiviral activity with AVPpred software (http://crdd.osdd.net/servers/avppred).

FRET experiments were performed between an HSV-1 particle with gB linked to the green fluorescent protein (HSV-1-gB-GFP) and fluorescent peptides (Aβ42-HiLyteFluor-555 (red)). Analysis of the virus has shown that its functionality remains intact despite the presence of GFP [29]. FRET experiments are a well-established way to determine whether two molecules with complementary green and red fluorescent labels are in close interaction (≤10 nm) [30]. When the green fluorescent label is excited, its emission can be transferred and excite a nearby red fluorescent label. These experiments usually employ fluorescence microscopy, but they also could be performed with thermocyclers equipped with laser induction and wavelength specific detectors. They measure fluorescence amplification created by dyes and can detect FRET when different fluorescents dyes are brought close together [31, 32]. If only green fluorescence is observed (excitation at 440 nm and emission at 580 nm) then no energy transfer has occurred. This would be expected when virus is tested alone or if the gB-GFP was more than 10 nm from the red dye linked to Aβ₄₂ peptides. If red fluorescence is measured in the channel with excitation at 440 nm (which does not efficiently excite red fluorophores) and emission at 660 nm, then GFP has transferred its energy to HiLyteFluor-555, which can then emit, giving values that are high on red axis and low on the green axis because the green fluorescence has been quenched by transfer to the red fluorophore. The observed values are presented in Fig. 2 and then analyzed statistically in Table 1.

Fig. 2

Energy transfer between HSV-1-gB-GFP and Aβ42-HiLyteFluor-555. A) Förster Resonance Energy Transfert process. B) Ratio of emitted green and red fluorescence in each well. Green fluorescence was emitted by HSV-1-gB-GFP particles and red fluorescence was emitted by Aβ₄₂-HiLyteFluor-555 when FRET occurs. Circles represent background measure, triangles represent HSV-1-gB-GFP/Aβ₄₂-HiLyteFluor-555 mix, stars represent HSV-1-gB-GFP particles alone, squares show results after NP40 pre-treatment of virus and diamonds represent results after pre-treatment of Aβ₄₂ with blocking antibodies. The dotted line identifies where green and red fluorescence emission are equal. n = 2-5 independent experiments in triplicate.

Table 1

Documentation of FRET between HSV-1-gB-GFP and Aβ₄₂-HiLyteFluor-555

	Mean±SD	Difference versus HSV-1-gB-GFP	Difference versus HSV-1-gB-GFP/Aβ₄₂-F555
HSV-1-gB-GFP	7.183±0.94	–	<0.0001^****
HSV-1-gB-GFP/Aβ₄₂-F555	4.415±0.35	<0.0001^****	–
HSV-1-gB-GFP/Aβ₄₂-F555 + α-Aβ₄₂-Ab	7.222±0.47	No	<0.0001^****
HSV-1-gB-GFP/Aβ₄₂-F555 + NP40	6.584±0.77	No	<0.0001^****

Significant differences were observed in the mean fluorescence between HSV-1-gB-GFP/Aβ42-HiLyteFluor-555 mix and HSV-1-gB-GFP, but also when Aβ₄₂-HiLyteFluor-555 was pre-treated with blocking antibodies or HSV-1-gB-GFP was pre-treated with NP40 prior to mixing. Unpaired T-test, two-tailed. ^****p < 0.0001. n = 2-5 independents experiments in triplicate.

Data showed that the green fluorescence emitted by HSV-1-gB-GFP alone (7.18±0.94 AU) was significantly higher than that emitted by the HSV-1-gB-GFP/Aβ₄₂-HiLyteFluor-555 mix (4.41±0.35 AU) (Table 1), whereas the mix gave much higher fluorescence in the red channel than the virus alone did. Indeed, the ratio of red fluorescence divided by green fluorescence was superior to 1 for the HSV-1-gB-GFP/Aβ₄₂-HiLyteFluor-555 mix, but inferior to 1 for HSV-1-gB-GFP alone. These results are consistent with FRET. We also observed that when HSV-1-gB-GFP was pre-treated with NP40 prior to mixing or when blocking antibodies directed against Aβ (α-Aβ₄₂-Ab) were pre-mixed with Aβ₄₂-HiLyteFluor-555, then mean green fluorescence values were 7.22±0.47 AU and 6.58±0.77 AU respectively, which are significantly different from the mean values without pre-treatment (4.41±0.35 AU), and similar to those obtained for HSV-1gB-GFP alone. Furthermore, the ratio of red to green fluorescence also decreased to values lower than 1 in the pre-treated samples. These latter results corresponded to an absence of FRET.

DISCUSSION

The purpose of the FRET experiments carried out in this study was to determine the mechanism of action of Aβ peptides against HSV-1 virus. The present results indicated that the fluorescent energy resulting from the excitation of the GFP associated with the gB of HSV-1 virions was transmitted to the fluorochrome HiLyteFluor-555 associated with the peptide Aβ₄₂. We concluded that FRET took place between the two fluorochromes, indicating that they are at a distance less than or equal to 10 nm [30]. Considering the proximity of Aβ₄₂ and gB validated by FRET, the diameter of the HSV-1 virion which measures approximately 200 to 250 nm [33, 34], and the diameter of HSV glycoprotein tetramers are probably close to 10 nm (glycoprotein D has been measured [35]), so we can therefore conclude that the Aβ₄₂ peptide must insert into the outer membrane of the virus, near the site on the viral membrane where gBs are present. This conclusion is supported by the works of Kagan et al. [25] and Lemkul et al. [26]. Both works described amyloid insertion into microbial membranes.

Controls show us that the energy transfer is prevented by the use of NP40 detergent, a non-ionic surfactant, which acts by disrupting membranes, so it cannot alter the peptides’ structure or direct interactions, suggesting that there is probably not a direct interaction between the peptide and the glycoprotein. The most logical explanation is that Aβ42 peptide is inserted into the viral envelope, near gB. When the detergent has solubilized the viral envelope, insertion is prevented. Blocking antibodies also interfere with HSV-1-gB/Aβ₄₂ interaction by preventing Aβ₄₂ peptide from inserting itself into the viral envelope.

Our observations support the hypothesis that Aβ peptides insert into the outer membrane of enveloped viruses in the same way as the LL-37 peptide. LL-37 is an α-helical peptide which inserts into lipid membranes and forms pores, deleterious to the integrity of the membrane and therefore to the organism or the target cell [36, 37]. The Aβ₄₂ peptide is also an α-helix and studies on cells or bacterial membranes have shown that it is also able to insert into lipid bilayers and form pores [25, 26]. It is also possible that the Aβ₄₂-HiLyteFluor-555 has integrated the corona as it has been shown to be present, but this would not explain the loss of infectivity. Indeed, it has been postulated that HSV-1 must be surrounded by a corona to be infectious.

Very recently, Wang et al. [38] have provided in silico evidence that Aβ associates with the HSV-1-gD. Our experimental observations by FRET of intact viral particles indicates that Aβ binds to viral particles near the binding site of gB or directly to gB. We proposed that this binding was via insertion of Aβ into the envelope of the virus akin to the proposed insertion of this peptide into bacterial and fungal membranes. It is entirely possible, however, that it binds to the viral particle via gD and that this binding interferes with the mechanism of fusion, necessary for infection, or that binding favors agglutination of viral particles, as proposed by the group of Moir and Tanzi [11]. It has been shown that gD and gB are attached to the viral membrane at separate location [34], and probably not physically close enough to allow FRET, so the binding of Aβ to gD observed by Wang et al., would not explain our observation of FRET. Since treatment of the virus with NP40 prevents FRET, but should not interfere with glycoprotein-Aβ interactions, we conclude that Aβ most probably does not bind gB.

Previously in our laboratory, we have established a microglia/neurons co-culture and we have measured several cytokines in supernatant after HSV-1 and/or Aβ adjunction [13]. We concluded in this paper that innate immune system respond to the infection and the presence of the peptide in the media. Our results shown here seem to confirm (at least in vitro) that the Aβ acts as an intracerebral component of the humoral innate immune system. Thus, it would recognize some molecular patterns characteristic for the neurotropic viruses (including, but not limited to the HSV-1) in a non- or semi-specific way, possibly similar to the interactions between the PAMPs and pathogen recognition receptors.

These experiments complement our previous and present results. When cells secret appropriate quantity of the Aβ₄₂ peptides in the presence of enveloped viruses, this will initiate an interaction resulting in the neutralization of the virus infectivity. With age, the most important risk factor of AD, microglial clearance capacity decreases, and cellular and viral waste accumulate in brain. When the quantity of virus or the resulting synthesis of Aβ₄₂ peptides increases, not only will the Aβ peptides inactivate the virus, but pathological interactions between the viruses, e.g., HSV-1, RSV, or SARS-CoV2 and Aβ peptides will result in the formation of traditional amyloid plaques. Upon further consideration, it can also be surmised that a biofilm or plaque may be advantageous both for the virus (protection) and for the cells (protection). The elucidation of these processes is of the most importance prior to using these conditions in a therapeutic perspective.

Conclusions

We concluded that there is indeed a close interaction, likely nonspecific or semi-specific, between the two types of molecules, which result in virus neutralization. Aβ peptides are antimicrobial peptides (AMP) that belongs to innate immune response and insert into viral envelop to disrupt them and prevent infection.

Footnotes

ACKNOWLEDGMENTS

Special thanks to Pr. Flore Rozenberg at Institut Cochin (Paris, France) for kindly providing us the HSV-1-gB-GFP.

FUNDING

KB, EHF, GD, and TF were supported by grants from the Canadian Institutes of Health Research (CIHR) (No. 106634), the Université de Sherbrooke, the Société des Médecins de l’Université de Sherbrooke (SMUS) and the Research Center on Aging.

SR was supported by Ikerbasque (The Basque Foundation for Science), by GV-AI-HEALTH, the Basque Government through the BERC 2018-2021 program, by the Spanish State Research Agency through BCAM Severo Ochoa excellence accreditation SEV-2017-0718 and through project RTI2018-093860B-C21 funded by (AEI/FEDER, UE) with acronym “MathNEURO”. MD and SR acknowledge the support of Inria via the Associated Team “NeuroTransSF”.

CONFLICT OF INTEREST

The authors declare no conflicts of interest.

References

Sanabria-Castro

, Alvarado-Echeverría

, Monge-Bonilla

(2017) Molecular pathogenesis of Alzheimer’s disease: An update. Ann Neurosci 24, 46–54.

Delaère

, He

, Fayet

, Duyckaerts

, Hauw

(1993) Beta A4 deposits are constant in the brain of the oldest old: An immunocytochemical study of 20 French centenarians. Neurobiol Aging 14, 191–194.

Mintun

(2005) Utilizing advanced imaging and surrogate markers across the spectrum of Alzheimer’s disease. CNS Spectr 10, 13–6.

Poul

F H-C

, Jorge

, Tom

, Andrew

, Abass

(2020) Amyloid hypothesis: The emperor’s new clothes? . J Alzheimers Dis 78, 1363–1366.

Fulop

, Witkowski

, Bourgade

, Khalil

, Zerif

, Larbi

, Hirokawa

, Pawelec

, Bocti

, Lacombe

, Dupuis

, Frost

(2018) Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimer’s disease? Front Aging Neurosci 10, 224.

Kinney

, Bemiller

, Murtishaw

, Leisgang

, Salazar

, Lamb

(2018) Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (NY) 4, 575–590.

Fischer

(1910) Die presbyophrene demenz, deren anatomische grundlage und klinische abgrenzung. Z Gesamte Neurol Psychiatr 3, 371–471.

Itzhaki

(2004) Herpes simplex virus type 1, apolipoprotein E and Alzheimer’ disease. Herpes Suppl 2, 77A–82A.

Wozniak

, Mee

, Itzhaki

(2009) Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol 217, 131–138.

10.

Bourgade

, Le Page

, Bocti

, Witkowski

, Dupuis

, Frost

, Fülöp

Jr (2016) Protective effect of amyloid-β peptides against herpes simplex virus-1 infection in a neuronal cell culture model. J Alzheimers Dis 50, 1227–1241.

11.

Kumar

, Choi

, Washicosky

, Eimer

, Tucker

, Ghofrani

, Lefkowitz

, McColl

, Goldstein

, Tanzi

, Moir

(2016) Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer’s disease. Sci Transl Med 8, 340.

12.

Moir

, Lathe

, Tanzi

(2018) The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement 12, 1602–1614.

13.

Bourgade

, Dupuis

, Frost

, Fülöp

Jr (2016) Anti-viral properties of amyloid-β peptides. J Alzheimers Dis 54, 859–878.

14.

Satpute-Krishnan

, DeGiorgis

, Bearer

(2003) Fast anterograde transport of herpes simplex virus: Role for the amyloid precursor protein of Alzheimer’s disease [published correction appears in Aging Cell 2010;9(3):454]. Aging Cell 2, 305–318.

15.

Satpute-Krishnan

, DeGiorgis

, Conley

, Jang

, Bearer

(2006) A peptide zipcode sufficient for anterograde transport within amyloid precursor protein. Proc Natl Acad Sci U S A 103, 16532–16537.

16.

Cheng

, Ferland

, Webster

, Bearer

(2011) Herpes simplex virus dances with amyloid precursor protein while exiting the cell. PLoS One 6, e17966.

17.

Pulina

, Hopkins

, Haroutunian

, Greengard

, Bustos

(2019) C99, not beta-amyloid, is associated with selective death of vulnerable neurons in Alzheimer’s disease. BioRxiv. doi: https://dx-doi-org.web.bisu.edu.cn/10.1101/527572.

18.

Idrees

, Kumar

(2021) SARS-CoV-2 spike protein interactions with amyloidogenic proteins: Potential clues to neurodegeneration. Biochem Biophys Res Commun 554, 94–98.

19.

Hsu

, Tien

, Yu

, Shen

, Lee

, Hsu

, Wang

, Chao

, Tsay

, Shie

(2021) The effects of Aβ1-42 binding to the SARS-CoV-2 spike protein S1 subunit and angiotensin-converting enzyme 2. Int J Mol Sci 22, 8226.

20.

Hensel

, Bauer

, Heinrich

, Spiegler

, Kayser

, Hempel

, Kraft

(2020) Challenges at the time of COVID-19: Opportunities and innovations in antivirals from nature. Planta Med 86, 659–664.

21.

Eimer

, Vijaya Kumar

, Navalpur Shanmugam

, Rodriguez

, Mitchell

, Washicosky

, György

, Breakefield

, Tanzi

, Moir

(2018) Alzheimer’s disease-associated β-amyloid is rapidly seeded by herpesviridae to protect against brain infection. Neuron 99, 56–63.

22.

Ezzat

, Pernemalm

, Pålsson

, Roberts

, Järver

, Dondalska

, Bestas

, Sobkowiak

, Levänen

, Sköld

, Thompson

, Saher

, Kari

, Lajunen

, Sverremark Ekström

, Nilsson

, Ishchenko

, Malm

, Wood

MJA

, Power

, Masich

, Lindén

, Sandberg

, Lehtiö

, Spetz

, El Andaloussi

(2019) The viral protein corona directs viral pathogenesis and amyloid aggregation. Nat Commun 10, 2331.

23.

Miklossy

(2016) Bacterial amyloid and DNA are important constituents of senile plaques: Further evidence of the spirochetal and biofilm nature of senile plaques. J Alzheimers Dis 53, 1459–1473.

24.

Bourgade

, Garneau

, Giroux

, Le Page

, Bocti

, Dupuis

, Frost

, Fülöp

Jr (2015) β-Amyloid peptides display protective activity against the human Alzheimer’s disease-associated herpes simplex virus-1. Biogerontology 16, 85–98.

25.

Kagan

, Jang

, Capone

, Teran Arce

, Ramachandran

, Lal

, Nussinov

(2012) Antimicrobial properties of amyloid peptides. Mol Pharm 9, 708–717.

26.

Lemkul

, Bevan

(2013) Aggregation of Alzheimer’s amyloid β-peptide in biological membranes: A molecular dynamics study. Biochemistry 52, 4971–4980.

27.

Bramucci

, Paiardini

, Bossa

, Pascarella

(2012) PyMod: Sequence similarity searches, multiple sequence-structure alignments, and homology modeling within PyMOL. BMC Bioinformatics 13(Suppl 4), S2.

28.

Thakur

, Qureshi

, Kumar

(2012) AVPpred: Collection and prediction of highly effective antiviral peptides. Nucleic Acids Res 40, 199–204.

29.

Potel

, Kaelin

, Gautier

, Lebon

, Coppey

, Rozenberg

(2002) Incorporation of green fluorescent protein into the essential envelope glycoprotein B of herpes simplex virus type 1. J Virol Methods 105, 13–23.

30.

Broussard

, Rappaz

, Webb

, Brown

(2013) Fluorescence resonance energy transfer microscopy as demonstrated by measuring the activation of the serine/threonine kinase Akt. Nat Protoc 8, 265–81.

31.

Zeng

, Liu

, McCabe

, Jones

DTW

, Ichimura

, Collins

(2009) Real-time quantitative polymerase chain reaction (qPCR) analysis with fluorescence resonance energy transfer (FRET) probes reveals differential expression of the four ERBB4 juxtamembrane region variants between medulloblastoma and pilocytic astrocytoma. Neuropathol Appl Neurobiol 35, 353–366.

32.

Martinez-Serra

, Robles

, Nicolàs

, Gutierrez

, Ros

, Amat

, Alemany

, Vögler

, Abelló

, Noguera

, Besalduch

(2014) Fluorescence resonance energy transfer-based real-time polymerase chain reaction method without DNA extraction for the genotyping of F5, F2, F12, MTHFR, and HFE. J Blood Med 5, 99–106.

33.

Bohannon

, Jun

, Gross

, Smith

(2013) Differential protein partitioning within the herpesvirus tegument and envelope underlies a complex and variable virion architecture. , E1613-E. Proc Natl Acad Sci U S A 110, 1620.

34.

Beilstein

, Cohen

, Eisenberg

, Nicolas

, Esclatine

, Pasdeloup

(2019) Dynamic organization of Herpesvirus glycoproteins on the viral envelope revealed by super-resolution microscopy. PLoS Pathog 15, e1008209.

35.

Pilling

, Rosenberg

, Willis

, Jäger

, Cohen

, Eisenberg

, Meredith

, Holzenburg

(1999) Three-dimensional structure of herpes simplex virus type 1 glycoprotein D at 2.4-nanometer resolution. J Virol 73, 7830–7834.

36.

Turner

, Cho

, Dinh

, Waring

, Lehrer

(1998) Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42, 2206–2214.

37.

Kai-Larsen

, Agerberth

(2008) The role of the multifunctional peptide LL-37 in host defense. Front Biosci 13, 3760–3767.

38.

Wang

, Zhang

, Zhao

, Wei

(2022) Molecular docking and molecular dynamics simulations studies on the protective and pathogenic roles of the amyloid-β peptide between herpesvirus infection and Alzheimer’s disease. J Mol Graph Model 113, 108143.